Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.36 |
| ▸ | PDE4A | P27815 | 6/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620108 | 1.00 | KAT2B (0.37) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL2761656 | 0.83 | PTGS2 (0.40) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| SCHEMBL27379609 | 0.80 | ALDH1A1 (0.34) | ALDH1A1HTR2C | |
| SCHEMBL23655043 | 0.73 | ALDH1A1 (0.48) | ALDH1A1HTR2C | |
| SCHEMBL24762718 | 0.72 | CNR2 (0.36) | ALDH1A1 | |
| SCHEMBL24762712 | 0.72 | CNR2 (0.36) | ALDH1A1 | |
| SCHEMBL27032900 | 0.72 | ALDH1A1 (0.40) | ALDH1A1HTR2C | |
| SCHEMBL29828872 | 0.70 | ALDH1A1 (0.40) | ALDH1A1HTR2C | |
| SCHEMBL30645756 | 0.70 | CA1 (0.47) | ALDH1A1HTR2C | |
| SCHEMBL2761782 | 0.68 | HPGD (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536713-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | Pfizer Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | HTR4, HTR1A, HTR3B | KAT2B 1801/4885BAZ2B 1262/4885PDE4D 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.